ARTICLE | Product Development
A tau mAb has achieved target clearance in Alzheimer’s patients
While the Phase II data at CTAD cast doubt on UCB’s bepranemab, they represent a critical advance for the field
November 1, 2024 9:18 PM UTC
Roche may not have seen enough promise in anti-tau mAb bepranemab to take it forward in Alzheimer’s disease, but Phase II data presented by former partner UCB provide some of the first clues about what species of tau to target and in which patients.
With the validation of β-amyloid as a modestly effective target for early Alzheimer’s disease, many companies have set their sights next on tau...